http://wso.sagepub.com/content/10/3/439.full
- Jeffrey L. Saver1,*
- Mayank Goyal2,3
- Alain Bonafe4
- Hans-Christoph Diener5
- Elad I. Levy6
- Vitor M. Pereira7
- Gregory W. Albers8
- Christophe Cognard9
- David J. Cohen10
- Werner Hacke11
- Olav Jansen12
- Tudor G. Jovin13
- Heinrich P. Mattle14
- Raul G. Nogueira15
- Adnan H. Siddiqui16
- Dileep R. Yavagal17
- Thomas G. Devlin18
- Demetrius K. Lopes19
- Vivek Reddy13
- Richard du Mesnil de Rochemont20
- Reza Jahan21
- for the SWIFT PRIME Investigators
- 1 Department of Neurology and Comprehensive Stroke Center, University of California Los Angeles, Los Angeles, CA, USA
- 2 Department of Radiology, University of Calgary, Calgary, AB, Canada
- 3 Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
- 4 Department of Neuroradiology, Hôpital Gui-de-Chauliac, Montpellier, France
- 5 Department of Neurology, University Hospital of University Duisburg-Essen, Essen, Germany
- 6 Department of Neurosurgery, State University of New York at Buffalo, Buffalo, NY, USA
- 7 Division of Neuroradiology, Toronto Western Hospital, Toronto, ON, Canada
- 8 Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA
- 9 Department of Diagnostic and Therapeutic Neuroradiology, University Hospital of Toulouse, Toulouse, France
- 10 Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA
- 11 Department of Neurology, University of Heidelberg, Heidelberg, Germany
- 12 Department of Radiology and Neuroradiology, Christian-Albrechts-University Kiel, Kiel, Germany
- 13 Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 14 Department of Neurology, Inselspital, University of Bern, Bern, Switzerland
- 15 Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
- 16 Department of Neurosurgery, Toshiba Stroke and Vascular Research Center, University at Buffalo State University of New York at Buffalo, Buffalo, NY, USA
- 17 Department of Neurology and Neurosurgery, University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL, USA
- 18 Division of Neurology, Erlanger Hospital at University of Tennessee, Chattanooga, TN, USA
- 19 Department of Neurosurgery, Rush University Medical Center, Chicago, IL, USA
- 20 Institute of Neuroradiology, Klinikum der Goethe-Universität, Frankfurt, Germany
- 21 Division of Interventional Neuroradiology, University of California Los Angeles, Los Angeles, CA, USA
- ↵* Correspondence: Jeffrey L. Saver, UCLA Stroke Center, 710 Westwood Plaza, Los Angeles, CA 90095, USA. E-mail: jsaver@ucla.edu
Abstract
Rationale Early
reperfusion in patients experiencing acute ischemic stroke is critical,
especially for patients with large vessel occlusion
who have poor prognosis without
revascularization. Solitaire™ stent retriever devices have been shown to
immediately restore
vascular perfusion safely, rapidly, and
effectively in acute ischemic stroke patients with large vessel
occlusions.
Aim The aim of the
study was to demonstrate that, among patients with large vessel,
anterior circulation occlusion who have received
intravenous tissue plasminogen activator,
treatment with Solitaire revascularization devices reduces degree of
disability
3 months post stroke.
Design The study is a
global multicenter, two-arm, prospective, randomized, open, blinded
end-point trial comparing functional outcomes
in acute ischemic stroke patients who are
treated with either intravenous tissue plasminogen activator alone or
intravenous
tissue plasminogen activator in combination with
the Solitaire device. Up to 833 patients will be enrolled.
Procedures Patients
who have received intravenous tissue plasminogen activator are
randomized to either continue with intravenous tissue
plasminogen activator alone or additionally
proceed to neurothrombectomy using the Solitaire device within six-hours
of symptom
onset.
Study Outcomes The
primary end-point is 90-day global disability, assessed with the
modified Rankin Scale (mRS). Secondary outcomes include
mortality at 90 days, functional independence
(mRS ≤ 2) at 90 days, change in National Institutes of Health Stroke
Scale at
27 h, reperfusion at 27 h, and thrombolysis in
cerebral infarction 2b/3 flow at the end of the procedure.
Analysis Statistical analysis will be conducted using simultaneous success criteria on the overall distribution of modified Rankin
Scale (Rankin shift) and proportions of subjects achieving functional independence (mRS 0–2).
Introduction
Stroke is the second leading cause of death and a leading cause of disability worldwide (1).
Cerebral infarction, due to thrombotic occlusion of a brain artery, is
the most common stroke type, accounting for 65–85%
of all cases. The only specific therapy of
demonstrated benefit for acute ischemic stroke (AIS) is intravenous (IV)
fibrinolysis
with tissue plasminogen activator (tPA) up to 4·5
hours after onset. However, patients with occlusions of large, proximal,
intracranial arteries are often not responsive to
IV tPA, as lytic therapy achieves early reperfusion in only 13–50% of
patients
with occlusions in the carotid terminus and the M1
segment of the middle cerebral artery (MCA) (2⇓⇓–5).
The Solitaire™ Flow Restoration (FR)
device is a self-expanding stent retriever that restores blood flow in
patients experiencing
ischemic stroke because of large intracranial
vessel occlusion. In multicenter registries and large clinical series,
the Solitaire
stent retriever has yielded high rates of
reperfusion and favorable clinical outcomes (6⇓–8).
In a randomized, head-to-head device trial, compared with
first-generation, coil retriever devices, use of the Solitaire™
FR was associated with superior recanalization
rates, faster achievement of reperfusion, reduced intracranial
haemorrhage
complications, and improved final disability
outcome (9).
The Solitaire™ with the Intention for
Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke
(SWIFT PRIME)
trial is being undertaken to establish the safety
and efficacy of neurothrombectomy with Solitaire in conjunction with IV
tPA vs. IV tPA alone, among AIS patients treatable
within six-hours of symptom onset.
No comments:
Post a Comment